MedTrace Logo

Evaluating Safety of Andiabet on Diabetes Mellitus Type II Patients, Phase I CT.

NCT04930679 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-06-18

No results posted yet for this study

Summary

This phase I clinical trial is used to evaluate the safety of Andiabet, a herbal-derived medicinal product that assists in the treatment of type 2 Diabetes (T2D). Thereby, determine efficacy of the drug on stabilizing blood glucose in T2D patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Andiabet

Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole

Sponsors & Collaborators

  • Centre of Clinical Pharmacology, Hanoi Medical University

    lead OTHER

Principal Investigators

  • Dung C Nguyen, MD · Center of Clinical Pharmacology, Hanoi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-24
Primary Completion
2019-02-22
Completion
2019-02-22

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930679 on ClinicalTrials.gov